Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Filings
22 filings of RUBICON since October 2025.
board outcome 8, presentation 6, transcript 5, acquisition 2, dividend 1
| Filed | Type | Subject | |
|---|---|---|---|
| 12 Nov 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Rubicon Research Limited has informed the Exchange about Transcript of Earnings Call Q2 FY 2026-27AI summaryRubicon Research Limited filed the transcript of its Q2 FY2026-27 earnings conference call held on November 5, 2026. Management (CEO Parag Sancheti) said Q2 revenue from operations was INR576 crores versus INR412 crores a year earlier, and PAT was INR90 crores versus INR54 crores; operating EBITDA was INR144 crores versus INR94 crores. Management (CFO Nitin Jajodia) said H1 revenue was INR1,111 crores, up 45%, and H1 PAT was INR175 crores, up 80%. Management guided operating EBITDA margin to 24% plus for the full year, up from the earlier 23% plus guidance. Management said four manufacturing facilities were inspected within the last six months, with observations at several sites that it described as procedural. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | presentation Acquisition, Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research Limited filed its Q2 FY2026-27 investor presentation (dated November 5, 2026) under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 revenue from operations was ₹5,764 million, up 39.9% year-on-year from ₹4,120 million in Q2 FY26; EBITDA was ₹1,464 million (up 54.1%) and PAT was ₹904 million (up 67.9%). H1 FY27 revenue was ₹11,107 million (up 45.3%) and H1 FY27 PAT was ₹1,752 million (up 80.3%). Management stated that net working capital days were 117 in H1 FY27 versus 126 for FY26, and that working capital would normalise to the typical 125-130 days over coming quarters. Management stated that the consolidated figures include the Arinna acquisition, with Arinna revenue of ₹194 million in Q2 FY27 (₹128 million in Q1 FY27), and that its EBITDA contribution is not material. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | board outcome Results | Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryBoard outcome filing: the Board of Rubicon Research Limited approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, at a meeting held November 5, 2026 (2:30 PM to 3:45 PM IST). Standalone revenue from operations was ₹3,835.72 million for the quarter ended September 30, 2026, versus ₹3,364.67 million in the quarter ended September 30, 2025 (figures as printed in the standalone table). Standalone net profit after tax was ₹606.20 million for the quarter ended September 30, 2026, versus ₹458.12 million in the corresponding quarter last year. Standalone revenue from operations for the half year ended September 30, 2026 was ₹8,113.02 million, versus ₹6,144.93 million for the half year ended September 30, 2025. Statutory auditor Deloitte Haskins & Sells LLP issued a limited review report stating nothing has come to its attention that the standalone statement has any material misstatement. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Aug 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Rubicon Research Limited has informed the Exchange regarding 'Transcript of Earnings Call Q1 FY 2026-27'.AI summaryRubicon Research filed the transcript of its Q1 FY27 earnings conference call held on August 14, 2026. Management reported Q1 revenue from operations of INR534 crores (up 51% year-on-year), EBITDA of INR131 crores (up 65%) and PAT of about INR85 crores (up more than 95%), with PAT including a one-off insurance claim gain in other income. Management said operating EBITDA margin was 24.2% and gross margin rose to 67.7%, and it revised its FY27 EBITDA margin guidance upward to around 23% from 22% to 23%. Management said the Pithampur facility is on track for commercial ramp-up from Q1 calendar 2027 after FDA observations were resolved, and that an acquired East Brunswick, New Jersey site (USD2.9 million) is expected to start commercialization in calendar 2027. Management said R&D spend was 10.9% of revenue and that INR251 crores of the INR500 crores nine-quarter R&D guidance has been spent so far. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | presentation Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research Limited filed its Q1 FY2026-27 investor presentation dated August 14, 2026. Q1 FY27 revenue from operations was ₹5,343 million, up 51.6% year-on-year from ₹3,525 million; EBITDA was ₹1,312 million (up 64.6%); PAT was ₹848 million (up 95.8%). Q1 FY27 figures include consolidation of Arinna post its acquisition, which contributed revenue of ₹128 million; the EBITDA contribution was not material. Q1 FY27 PAT includes a one-off other income of ₹36 million (insurance claim on goods lost in transit); Pre-R&D EBITDA margin was 35.0% and ROACE (annualized, pre-tax) was 36%. Management said net working capital days were 114 in Q1 FY27 versus 126 for FY26, and expects them to normalize to the typical 125-130 days over coming quarters. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | presentation Acquisition, Capex, Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research Limited filed its Q1 FY2026-27 investor presentation dated August 14, 2026. Q1 FY27 revenue from operations was ₹5,343 million, up 51.6% year-on-year from ₹3,525 million; EBITDA was ₹1,312 million (up 64.6%) and PAT was ₹848 million (up 95.8%). Q1 FY27 figures include consolidation of Arinna from closing of its ₹1,759 million acquisition; Arinna contributed revenue of ₹128 million, with EBITDA contribution described as not material. Management said net working capital days were 114 in Q1 FY27 versus 126 for FY26 due to quarterly fluctuations, and expects it to normalise to the typical 125-130 days over coming quarters. Management stated ROACE (annualised, pre-tax) was 36% in both 30-Jun-26 and 31-Mar-26 periods, after capital employed in pre-revenue assets of ₹3,537 million (Pithampur plant, new CSN facility and Arinna). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | board outcome Acquisition, Results | Rubicon Research Limited has submitted to the Exchange, the financial results for the quarter ended Jun 30, 2026.AI summaryRubicon Research Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on August 14, 2026. Standalone revenue from operations for Q1 FY27 was ₹4,277.30 million, up from ₹2,780.26 million in the year-ago quarter, and net profit after tax was ₹824.49 million versus ₹351.52 million. Basic EPS for the quarter was ₹4.99 (not annualised) against ₹2.28 a year earlier. The filing also notes the Scheme of Amalgamation of Kia Health Tech Private Limited with the company, filed with the Registrar of Companies on August 3, 2026, and an 85% stake acquisition in Arinna Lifesciences Limited for ₹1,759.17 million, completed on April 30, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Jul 2026 | board outcome Acquisition, Dividend / buy-back, Legal | Rubicon Research Limited has informed the Exchange regarding Outcome of Board Meeting held on July 20, 2026.1. Date of 27th Annual General Meeting and Record Date for payment of final dividend on equity shares for the financial year 2025-26AI summaryBoard of Rubicon Research Limited, at its meeting held July 20, 2026, fixed the 27th AGM for Wednesday, August 26, 2026, through video conferencing or other audio-visual means. The Board fixed Friday, August 7, 2026 as the record date for final dividend of ₹1.50 per equity share (face value ₹1 each) for FY 2025-26, recommended on May 29, 2026, subject to member approval and tax deduction at source. The dividend will be paid within 30 days from the date of approval, to members whose names are in the Register of Members or depository records as of August 7, 2026. The Board approved the Scheme of Merger of wholly owned subsidiary Kia Health Tech Private Limited with the Company, under Section 233 of the Companies Act, 2013, with an appointed date of April 1, 2026. No shares will be issued and no consideration is payable under the merger, so there is no change in shareholding pattern or voting rights; the scheme remains subject to statutory, regulatory, shareholder and creditor approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jun 2026 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Results | Rubicon Research Limited has informed the Exchange regarding 'Earnings Call Transcript'.AI summaryRubicon Research filed the transcript of its Q4 FY26 earnings call held on May 29, 2026. Management reported Q4 FY26 revenue of INR 5,140 million (up 44% year-on-year), operating EBITDA of INR 1,190 million (up 64%) and PAT of INR 768 million (up 112%); full-year revenue was INR 17,540 million (up 37%) and PAT was INR 2,467 million (up 84%). Management said the board recommended a dividend of INR 1.5 per share (150%), and that the Pithampur facility ramp-up is still expected in Q1 CY27 with EBITDA guided at 22% to 23%. Management said it will rely more on outsourced manufacturing for at least a couple more quarters due to demand above expectations and internal manufacturing constraints, which weighed slightly on gross margins. Management described the acquisition of an 85% stake in Arinna Lifesciences for an enterprise value of INR 200 crores on a cash and debt-free basis (deal value about INR 176 crores) and a proposed ESOP pool subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | dividend Dividend / buy-back, Results | Rubicon Research Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 1.50 per equity share.AI summaryRubicon Research Limited filed the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, approved by the Board on May 29, 2026, with an unmodified auditor opinion from Deloitte Haskins & Sells LLP. The Board recommended a final dividend of INR 1.50 per equity share (face value INR 1), for the financial year ended March 31, 2026. The dividend is subject to declaration by members at the ensuing AGM and will be paid within 30 days of that declaration. The CFO confirmed the unmodified audit opinion under Regulation 33(3)(d) of the SEBI Listing Regulations. The Board meeting ran from 2:30 PM to 4:10 PM (IST). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Acquisition, Dividend / buy-back | Formulation, adoption and implementation of Rubicon Research Limited - Employees Stock Option Scheme 2026AI summaryBoard of Rubicon Research Limited approved formulation of the Rubicon Research Limited - Employees Stock Option Scheme 2026 for grant of employee stock options to eligible employees of the company and its subsidiaries, subject to member and regulatory approvals. Up to 24,84,415 stock options, each corresponding to one equity share of INR 1 face value, may be granted in one or more tranches; this includes 6,72,162 balance pool available under the existing Scheme 2022. Exercise price shall not be less than the face value of the equity shares. Time for exercise and significant terms will be disclosed when member approval is sought. The board meeting commenced at 2:30 PM IST and concluded at 4:10 PM IST on May 29, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | presentation Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research filed its Q4 FY2025-26 investor presentation dated May 29, 2026, with BSE and NSE. Q4 FY26 revenue from operations was ₹5,139 million, up 43.5% year-on-year from ₹3,581 million; PAT was ₹768 million, up 111.8% from ₹362 million. Q4 FY26 EBITDA (including other income) was ₹1,213 million, up 67.2%; EBITDA margin was 23.6%. For FY26, revenue from operations was ₹17,540 million (up 36.6%) and PAT was ₹2,467 million (up 83.6%); fully diluted EPS was ₹15.31. Shareholders' funds rose to ₹12,888 million at March 31, 2026 from ₹5,410 million a year earlier; ROACE (annualized, pre-tax) was 36%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Dividend / buy-back, Results | Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryRubicon Research Limited's board, at its meeting on May 29, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The statutory auditor, Deloitte Haskins & Sells LLP, issued unmodified audit opinions on the results, and the CFO has confirmed this. The board recommended a dividend of INR 1.50 per equity share (face value INR 1), subject to shareholder approval at the AGM, payable within 30 days of that approval. The board meeting ran from 2:30 PM to 4:10 PM (IST). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 Apr 2026 | acquisition Acquisition | Rubicon Research Limited has informed the Exchange about AcquisitionAI summaryRubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Limited, which will become a subsidiary on acquisition. Arinna is a Ahmedabad-based branded pharmaceutical marketing company focused on the CNS/neuro-psychiatric segment; turnover was INR 71.5 crores in FY 2024-25 (INR 65.14 crores in FY 2023-24, INR 60.06 crores in FY 2022-23). Enterprise value is INR 200 crores on a cash and debt free basis; purchase consideration is approximately INR 175.92 crores in cash at about INR 158.53 per share on a fully diluted basis. Completion is expected within one month of signing the transaction documents; no governmental or regulatory approvals are required, and the acquisition is not a related party transaction. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Feb 2026 | transcript Capex, Guidance, Results | Rubicon Research Limited has informed the Exchange about TranscriptAI summaryRubicon Research filed the transcript of its Q3 FY2025-26 earnings conference call held on February 3, 2026. Management reported Q3 revenue from operations of INR 476 crores (up 52% YoY), EBITDA of INR 112 crores (up 59%), PAT of INR 73 crores (up 91%) and EPS of INR 4.41. CFO Nitin Jajodia said 9M revenue was INR 1,240 crores (up 34%) and 9M PAT-type EBITDA after other income was INR 287 crores, with R&D spend at about 10.8% of revenue. CEO Parag Sancheti said the operating EBITDA margin would remain stable at 22% to 23%, while outsourcing due to higher-than-expected demand is pressuring gross margin in the near term. Management said Pithampur facility is expected to be operationalised by mid-2026 and commercialised in Q1 CY2027, and that R&D spend is expected to stay above INR 500 crores over FY26 to Q1 FY28. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2026 | board outcome Acquisition, Legal, Management change | Rubicon Research Limited has informed the Exchange regarding Board meeting held on February 03, 2026.AI summaryRubicon Research Limited filed the outcome of its board meeting held on February 3, 2026 (meeting ran from 3:00 PM to 4:30 PM IST). The board approved the appointment of Dr. Pradnya Saravade as Additional Independent Woman Director for three years, from February 3, 2026 to February 2, 2029, subject to shareholder approval. Mr. Anand Agarwal, Non-Executive Director nominated by General Atlantic Singapore RR Pte Ltd, resigned effective close of business on February 3, 2026; the board noted the resignation. The board approved the appointment of M/s. BNP & Associates, Practicing Company Secretaries, as Secretarial Auditor for FY 2025-26 and for FY 2026-27 to FY 2029-30, subject to shareholder approval. The board granted in-principle approval for the merger of wholly owned subsidiary KIA Health Tech Private Limited with Rubicon Research Limited, subject to a board-approved scheme of arrangement and regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2026 | board outcome Legal, Results | Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryRubicon Research Limited's board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, at a meeting held February 3, 2026 (3:00 PM to 4:30 PM IST). The filing encloses the results and the statutory auditor's limited review report, which states no modification of conclusion. The auditor draws attention to Note (x) on a GST Department search/inspection at the parent company's premises after December 31, 2025; the conclusion is not modified for this matter. The auditor did not review four subsidiaries, whose consolidated revenue was Rs. 655.01 million for the quarter and Rs. 1,750.32 million for nine months, with net loss after tax of Rs. 28.40 million and Rs. 71.21 million respectively. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2026 | presentation Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research Limited filed its Q3 FY2025-26 Investor Presentation dated February 3, 2026, under Regulation 30 of the SEBI LODR Regulations. Q3 FY26 revenue from operations was ₹4,755 million, up 51.7% from ₹3,134 million in Q3 FY25. Q3 FY26 EBITDA was ₹1,119 million (up 59.0% year-on-year) and PAT was ₹728 million (up 91.2% year-on-year). For 9M FY26, revenue from operations was ₹12,400 million (up 33.9%) and PAT was ₹1,700 million (up 73.2%). Fully diluted EPS for Q3 FY26 was ₹4.41, against ₹2.46 in Q3 FY25. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Nov 2025 | transcript Capex, Guidance, Results | Rubicon Research Limited has informed the Exchange about TranscriptAI summaryRubicon Research filed the transcript of its Q2 FY 2025-26 earnings conference call held on 13 November 2025. Management said revenue grew 39% year-on-year, operating EBITDA grew 53%, and PAT was 56% higher than the previous year, with annualized ROACE of 36% for the quarter (CEO Parag Sancheti). CFO Nitin Jajodia said gross margin was 68.7% and EBITDA margin 22.9%, with EBITDA margin expected to sustain at current levels and gross margin trending towards 68%. Management guided R&D spend at 10% to 11% of operating revenue over the next 3 to 4 years, and said specialty products contributed 32.5% of gross profit for the quarter. Management said the Pithampur plant is expected to be operationalized in May 2026 and that outsourced manufacturing will continue until then. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | presentation Capex, Guidance, Results | Rubicon Research Limited has informed the Exchange about Investor PresentationAI summaryRubicon Research Limited filed its Investor Presentation dated 13 November 2025 for the quarter and half year ended 30 September 2025 (Q2 FY26). Q2 FY26 operating revenue was ₹4,120 millions, up 39.2% YoY from ₹2,960 millions; operating EBITDA was ₹943 millions (up 52.9% from ₹617 millions); PAT was ₹539 millions (up 56.2% from ₹345 millions). USD revenue was $47 mn for Q2 FY26, up 33% YoY and up 11.9% QoQ, per the presentation. Management said gross margin fell to 68.7% due to higher outsourced manufacturing, while EBITDA margin rose to 22.9%, and that outsourcing is expected to continue until the Pithampur plant ramps up in Q1 CY2027. Management said cash flow from operations for the quarter was ₹605 Mn and that two product approvals were received in Q2. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | board outcome Results | Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBoard of Rubicon Research Limited approved standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2025 at a meeting held on 13 November 2025, with a limited review report from Deloitte Haskins & Sells LLP. Standalone revenue from operations for Q2 FY26 (quarter ended 30 September 2025) was Rs 3,364.67 million, up from Rs 2,548.98 million a year earlier; half-year revenue was Rs 6,144.93 million versus Rs 5,281.64 million. Standalone net profit after tax for the quarter was Rs 458.12 million (September 2024 quarter: Rs 428.87 million); half-year net profit was Rs 809.64 million (Rs 890.42 million a year earlier). Standalone basic EPS for the quarter was Rs 2.97 (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Oct 2025 | acquisition Acquisition | Rubicon Research Limited has informed the Exchange about AcquisitionAI summaryRubicon Research Limited has entered into a definitive agreement with Neuronasal, Inc. to acquire common stock in tranches for total consideration of up to USD 2.5 million. The acquisition is a minority investment for up to approximately 10.5% of Neuronasal's common stock, subject to achievement of all milestones. Consideration is in kind, a milestone-based share issuance against development activities undertaken by the Company up to 31 March 2027. Neuronasal is a pre-revenue clinical stage pharmaceutical company developing CNS disease treatments, based in Wexford, Pennsylvania, USA, incorporated January 3, 2014; FY24 net worth was USD 2,745,773.90. The acquisition is not a related party transaction and no governmental or regulatory approvals are required. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.